摘要
目的:探索用卡铂联合多西他赛作为一线方案治疗晚期非小细胞肺癌(NSCLC),静脉血中循环内皮细胞(CECs)数目在预测化疗有效性中的作用。方法:采用卡铂联合多西他赛治疗晚期NSCLC病人53例,用流式细胞术测定NSCLC病人外周静脉血中CECs数目,同样方法测定健康人静脉血中CECs数目。结果:NSCLC病人化疗前的外周静脉血中CECs数目[(1 798±970)个/mL]明显高于健康人[(135±150)个/mL]。将化疗前CECs数目视为基线值,Ⅳ期病人的基线CECs数目高于IIIB病人(P=0.036)。基线CECs数目和肿瘤体积呈明显正相关性(rs=0.556,P<0.001)。化疗后病人CECs数目明显下降[化疗第22天为(704±603)个/mL],其中临床获益病人CECs数目下降较明显,病情进展(PD)病人CECs数目无明显下降。临床获益病人基线CECs数目明显高于PD病人(P=0.011)。结论:CECs数目可用来预测卡铂联合多西他赛治疗晚期NSCLC的有效性。
Objective： To investigate the role of circulating endothelial cells （CECs） as a marker to predict the effect of a carboplatin and docetaxel based first line chemotherapy in advanced non-small cell lung cancer （NSCLC）. Methods： Fifty-three NSCLC patients were treated with carboplatin combined with docetaxel. Levels of CECs were measured by flow cytometry. Results：The CECs count before chemotherapy （baseline value） was significantly higher in NSCLC patients than in healthy volunteers[（1 798±970）/mL and （135±150）/mL, respectively]. The baseline CECs values of patients with stage IV NSCLC were significantly higher than those in patients with stage IIIB NSCLC （P=0.036）.The correlation between the baseline CECs count and tumor volnme was positive （r, =0.556, P〈0.001）. CECs were decreased by chemotherapy as compared to baseline values [（704±603）/mL, d22]. The decrease was more significant in patients with clinical benefit while the PD group patients didn＇t show this change. CECs values of clinical benefit group was significantly higher than PD group （P=0.011）. Conclusion：As a marker, CECs can be useful in predicting the clinical effect of the carboplatin combined with doeetaxel on patients with advanced NSCLC.
出处
《天津医科大学学报》
2014年第5期366-369,共4页
Journal of Tianjin Medical University
关键词
循环内皮细胞
非小细胞肺癌
化疗
circulating endothelial cell
non-small cell lung cancer
chemotherapy
